SCHEMBL3148977

SCHEMBL3148977

CCOC(=O)C(C)(C)Sc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 2/20 0.52
NR1H4 Q96RI1 1/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
MAOB P27338 1/20 0.49
PRKCA P17252 1/20 0.48
PRKCD Q05655 1/20 0.48
ALOX5 P09917 2/20 0.48
PTPRZ1 P23471 1/20 0.48
NR4A1 P22736 1/20 0.48
NR4A2 P43354 1/20 0.48
NR4A3 Q92570 1/20 0.48
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46
ADRB3 P13945 1/20 0.46
RAB9A P51151 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464689 0.83 PIN1 (0.50) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL6036021 0.80 L3MBTL1 (0.58) L3MBTL1LMNAALDH1A1NR1H4MEN1
SCHEMBL4428685 0.80 PPARG (0.61) L3MBTL1LMNAALDH1A1NR1H4MEN1
SCHEMBL1464321 0.79 ALDH1A1 (0.50) L3MBTL1LMNAALDH1A1KMT2AKDM4E
SCHEMBL15669148 0.79 L3MBTL1 (0.56) L3MBTL1LMNAALDH1A1NR1H4MEN1
SCHEMBL6504864 0.79 MMP8 (0.63) L3MBTL1LMNAALDH1A1NR1H4MEN1
SCHEMBL3344926 0.79 CA12 (0.47) LMNAALDH1A1KMT2AKDM4EMAPT
SCHEMBL5992353 0.79 L3MBTL1 (0.53) L3MBTL1LMNAALDH1A1NR1H4MEN1
SCHEMBL5885017 0.78 MAOB (0.57) L3MBTL1LMNAALDH1A1NR1H4MEN1
SCHEMBL5660644 0.78 OPRK1 (0.60) L3MBTL1LMNAALDH1A1NR1H4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137401-A1 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2010-06-03 US disclosed
US-7687665-B2 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor INCYTE CORPORATION (US) 2010-03-30 US disclosed
EP-1768954-A4 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-05-28 EP disclosed
EP-1768954-A2 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-04 EP disclosed
WO-2006002361-A2 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-01-05 WO disclosed
US-20050288329-A1 2-Methylprop anamides and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137401-A1 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD3B1 L3MBTL1 4544/4885LMNA 2353/4885ALDH1A1 82/4885
US-20050288329-A1 2-Methylprop anamides and their use as pharmaceuticals HSD11B1, HSD11B2, HSD3B1 L3MBTL1 4544/4885LMNA 2353/4885ALDH1A1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.